Increased plasma microRNA and CD133/CK18-positive cancer cells in the pleural fluid of a pancreatic cancer patient with liver and pleural metastases and correlation with chemoresistance

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 691-694

  Ren, Chuanli ^a   Chen, Hui ^a   Han, Chongxu ^a   Wang, Daxin ^a   Fu, Deyuan ^a  

^a CLINICAL MEDICAL COLLEGE OF YANGZHOU UNIVERSITY   (China)

Author keywords

CD133; Liver metastases; Pancreatic cancer; Plasma microRNA; Pleural fluid; Tailored therapy

Indexed keywords

ALKALINE PHOSPHATASE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD133 ANTIGEN; CD45 ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; MICRORNA; MICRORNA 103; MICRORNA 151; MICRORNA 21; MICRORNA 25; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; ALCOHOLISM; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; CANCER CELL; CANCER MORTALITY; CANCER PATIENT; CANCER SIZE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; GIEMSA STAIN; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMAGNETIC SEPARATION; LIVER METASTASIS; MALE; ORGAN PERFUSION; PANCREAS CANCER; PLEURA EFFUSION; PLEURA FLUID; PLEURA METASTASIS; PROTEIN BLOOD LEVEL; STOMACH DISTENSION;

EID: 84864644681     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.798     Document Type: Article

References (14)

1. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007.
2. Wang Z, Li Y, Ahmad A, et al: Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33, 2011.
3. Stokes JB, Adair SJ, Slack-Davis JK, et al: Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther 10: 2135-2145, 2011.
4. Ren C, Han C, Zhang J, et al: Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy. Cancer Biol Ther 12: 700-706, 2011.
5. Liu J, Gao J, Du Y, et al: Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131: 683-691, 2011.
6. Park JY, Helm J, Coppola D, Kim D, Malafa M and Kim SJ: MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol 17: 817-827, 2011.
7. Roldo C, Missiaglia E, Hagan JP, et al: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24: 4677-4684, 2006.
8. Ren C, He P, Zhang J, Zheng Z, Qian Y and Zhao X: Malignant characteristics of circulating tumor cells and corresponding primary tumor in a patient with esophageal squamous cell carcinoma before and after surgery. Cancer Biol Ther 11: 633-638, 2011.
9. Rhim AD, Mirek ET, Aiello NM, et al: EMT and dissemination precede pancreatic tumor formation. Cell 148: 349-361, 2012.
10. Ascoli V, Taccogna S, Scalzo CC and Nardi F: Utility of cytokeratin 20 in identifying the origin of metastatic carcinomas in effusions. Diagn Cytopathol 12: 303-308, 1995.
11. Yao J, An Y, Wie JS, et al: Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines. Swiss Med Wkly 141: w13208, 2011.
12. Giovannetti E, Funel N, Peters GJ, et al: MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70: 4528-4538, 2010.
13. Ali S, Ahmad A, Banerjee S, et al: Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70: 3606-3617, 2010.
14. Moriyama T, Ohuchida K, Mizumoto K, et al: MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 8: 1067-1074, 2009.